MYCN and neoplasm: Moreover, MYCN plays a pivotal role in maintaining NEPC, and interrupting MYCN through AURKA inhibitor CD532 leads to a notable decrease in tumor burden in patient-derived xenograft mice carrying N-Myc/myrAKT1 tumors.94